Akcea Therapeutics Inc (AKCA) Return on Equity ROE from the second quarter 2020 to second quarter 2019 and annually, average high and low, overall ranking from Jun 30 2020 to Jun 30 2019 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Akcea Therapeutics Inc   (NASDAQ: AKCA)

Akcea Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Akcea Therapeutics Inc in the second quarter 2020?
Akcea Therapeutics Inc recorded a cumulative net loss of $-42 million during 12 months ending in the second quarter 2020, resulting in a negative return on equity (ROE) of -8.94%.

Within the Major Pharmaceutical Preparations industry 71 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2020 from 0 to 2591.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter
Y / Y Equity Change 29.94 % 31.07 % 96.23 % 15.66 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -42 -29 41 -112 -144
Return On Equity (TTM) -8.94 % -6.7 % 10.03 % -33 % -43.87 %
AKCA's Total Ranking # 2591 # 0 # 1553 # 0 # 0
Equity (TTM) in Millions 479 510 543 325 369
Seq. Equity Change -6.02 % -6.13 % 66.83 % -11.71 % -5.2 %
Seq. Net Income Change - - - - -

Back to AKCA Management Effectiveness >> AKCA's 5 Years Annual ROE >> Compare AKCA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 72
Sector # 220
Overall # 2591

Return On Equity Statistics
High Average Low
10.03 %
-1.87 %
-8.94 %
(Dec 31 2019)   (Jun 30 2020)





AKCA Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2015)
2017

Total Equity in Millions 543 277 -18 0 0
Y / Y Equity Change 96.23 % - - - -
Net Income in Millions 41 -226 -61 0 0
Y / Y Net Income Change - - - - -
Return On Equity 7.51 % -81.61 % - - -

Back to AKCA Management Effectiveness >> AKCA's 5 Years Annual ROE >> Compare AKCA ROE to its Competitors




Annual Roe Comment
In 2019 ROE improved to 7.51 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AKCA's' Return on Equity at Yahoo Finance
AKCA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AKCA's Competitors
Subscribers only: Roe for Akcea Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for AKCA's Customers




Companies with similar Return On Equity at Jun 30 2020, within Healthcare Sector ROE

Date modified: 2026-08-29T17:40:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.